La Jolla Pharmaceutical Co.

Great News! Now you can buy fractional shares of La Jolla Pharmaceutical Co.

What is Fractional Shares?

Fractional shares are pieces of one full share of a company or exchange-traded fund (ETF).

In INDmoney, you can buy La Jolla Pharmaceutical Co. stock in any dollar amount, or any other stock you want.

$10

$50

$100

LJPC

La Jolla Pharmaceutical Co. (LJPC)

Q: What is La Jolla Pharmaceutical Co. (LJPC) share price today?

La Jolla Pharmaceutical Co. (LJPC) share price today is $4.58

Q: Can Indians buy La Jolla Pharmaceutical Co. (LJPC) shares?

Yes, Indians can buy La Jolla Pharmaceutical Co. (LJPC) shares. As per RBI rule, an Indian citizen can invest 250,000 dollars a year in foreign markets.

Q: How can I buy La Jolla Pharmaceutical Co. (LJPC) shares from India?

Three ways to invest in La Jolla Pharmaceutical Co. (LJPC) stocks from India are 1.Investment through apps: INDmoney is one of the leading apps that help you invest in La Jolla Pharmaceutical Co. (LJPC) stocks from India 2.Investment through Indian brokers tied up with a foreign broker 3.Investment by opening an account with a Foreign broker

Q: Can Fractional shares of La Jolla Pharmaceutical Co. (LJPC) be purchased?

You can buy just a fraction of La Jolla Pharmaceutical Co. (LJPC) shares.

Q: What are the documents required to start investing in La Jolla Pharmaceutical Co. (LJPC) stocks?

You will need a proof of Identification (PAN, Aadhaar etc) and proof of address (Aadhaar, Voter ID etc) to invest in La Jolla Pharmaceutical Co. (LJPC) stocks . The entire process is paperless and can be completed seamlessly.

$4.580.66%▲

Key Stats

Open	$4.45
Today Low/High	$4.38 / $4.58
52 Week Low/High	$3.35 / $7.85
Market Cap	$125.23M

Company Details

La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.